← The Wire
EYPTNasdaq
EyePoint, Inc.
Laboratory Analytical Instruments · DE · CIK 1314102
EyePoint develops and commercializes therapeutics for serious retinal diseases, aiming to improve patient lives and reduce follow-up care frequency
red 8-K · 90d
$1.09B
Market cap
$14.11
Last close
+3.3%
1D
+2.8%
5D
1.6M
Volume
Price · last 39 sessions+1.9%
May 4L $11.45 · H $14.40Jun 29
396
Total filings
Jun 22, 2026
Last filing
12/31
Fiscal year end
8-KExecutive Change · Shareholder VoteJun 22, 20268-KCompany UpdateMay 14, 202610-Q10-QMay 7, 20268-KResults of OperationsMay 6, 2026DEFA14ADEFA14AApr 27, 2026DEF 14ADEF 14AApr 27, 20268-KCompany UpdateApr 13, 20268-KReg FD DisclosureMar 20, 202610-K10-KMar 5, 20268-KResults of OperationsMar 4, 20268-KCompany UpdateMar 2, 20268-KResults of OperationsJan 7, 20268-KBylaw AmendmentDec 8, 20258-KCompany UpdateNov 19, 20258-KCompany UpdateNov 6, 2025424B5424B5Nov 6, 202510-Q10-QNov 6, 20258-KResults of OperationsNov 5, 20258-KMaterial Agreement · Company UpdateOct 17, 2025424B5424B5Oct 16, 2025424B5424B5Oct 14, 20258-KResults of Operations · Company UpdateOct 14, 202510-Q10-QAug 7, 20258-KResults of OperationsAug 6, 20258-K/ACompany UpdateJul 29, 20258-KCompany UpdateJul 29, 20258-KExecutive Change · Shareholder VoteJun 20, 20258-KCompany UpdateMay 27, 2025DEFA14ADEFA14AMay 9, 202510-Q10-QMay 8, 20258-KResults of Operations · Company UpdateMay 7, 2025DEFA14ADEFA14AApr 28, 2025DEF 14ADEF 14AApr 28, 202510-K10-KMar 6, 20258-KResults of OperationsMar 5, 20258-KCompany UpdateMar 4, 20258-KCompany UpdateFeb 5, 20258-KResults of Operations · Company UpdateJan 13, 20258-KExecutive Change · Company UpdateJan 8, 20258-KCompany UpdateDec 4, 2024SC 13GSC 13GNov 8, 2024SC 13GSC 13GNov 7, 202410-Q10-QNov 7, 20248-KResults of OperationsNov 7, 20248-KMaterial Agreement · Company UpdateOct 31, 2024424B5424B5Oct 30, 2024424B5424B5Oct 28, 20248-KResults of Operations · Company UpdateOct 28, 20248-KCompany UpdateOct 24, 2024SC 13GSC 13GOct 22, 20248-KExecutive Change · Company UpdateSep 4, 202410-Q10-QAug 8, 20248-KResults of OperationsAug 7, 20248-KResults of Operations · Company UpdateJun 26, 20248-KExecutive Change · Shareholder VoteJun 21, 20248-KCompany UpdateMay 28, 202410-Q10-QMay 9, 20248-KResults of OperationsMay 8, 20248-KCompany UpdateMay 6, 2024SC 13GEYEPOINT PHARMACEUTICALS, INC.Apr 30, 2024DEF 14ADEF 14AApr 26, 2024DEFA14ADEFA14AApr 26, 202410-K10-KMar 8, 20248-KResults of OperationsMar 7, 20248-KCompany UpdateMar 4, 2024SC 13GSC 13GFeb 14, 20248-KResults of Operations · Company UpdateJan 10, 20248-KCompany UpdateDec 8, 20238-KMaterial Agreement · Company UpdateDec 8, 2023424B5424B5Dec 7, 2023424B5424B5Dec 4, 20238-KCompany UpdateDec 4, 20238-KCompany UpdateNov 9, 202310-Q10-QNov 3, 20238-KResults of OperationsNov 1, 20238-KExecutive Change · Company UpdateOct 16, 20238-KCompany UpdateSep 13, 20238-KCompany UpdateSep 11, 202310-Q10-QAug 4, 20238-KResults of OperationsAug 2, 2023
Insider Activity
In the 90 days to Mar 16, 2026: 1 insider bought $20K · 1 sold $808K.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 16, 2026 | Duker Jay S.President and CEO | Buy | 1,500 | $13.15 | $20K |
| Mar 4, 2026 | Ribeiro RamiroChief Medical Officer | Sell | 2,438 | $17.87 | $44K |
| Feb 17, 2026 | Ribeiro RamiroChief Medical Officer | Sell | 2,437 | $15.00 | $37K |
| Jan 5, 2026 | Ribeiro RamiroChief Medical Officer | Sell | 42,544 | $17.10 | $728K |
| Dec 4, 2025 | Cormorant Asset Management, LpOther | Sell | 60,000 | $15.70 | $942K |
| Dec 4, 2025 | Lurker NancyDirector | Sell | 9,300 | $15.11 | $141K |
| Nov 28, 2025 | Lurker NancyDirector | Sell | 500 | $14.95 | $7K |
| Nov 26, 2025 | Lurker NancyDirector | Sell | 200 | $14.95 | $3K |
| Nov 11, 2025 | Ribeiro RamiroChief Medical Officer | Sell | 2,722 | $11.61 | $32K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.
Similar companies
Comparable business profile · signals at a glance